Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers, Not Eligible for Initial Sequencing in Clinical Routine and Selected From the First Line in Molecular Tumour Board.

NCT06958224 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT06958224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06958224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers, Not Eligible for Initial Sequencing in Clinical Routine and Selected From the First Line in Molecular Tumour Board.
Lead sponsor
University Hospital, Lille
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 10, 2026
Completion date
January 9, 2029
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, liver cancer, pancreatic ductal adenocarcinoma